Clinical Trial: Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA

U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT07532408) titled 'Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA' on April 08.

Brief Summary: This study aimed to explore the efficacy and safety of romiplostim N01 in the treatment of relapsed/refractory chemoradiotherapy-induced aplastic anemia

Study Start Date: April, 2026

Study Type: INTERVENTIONAL

Condition: Aplastic Anemia

Intervention: DRUG: Romiplostim N01

Romiplostim N01 20 µg/kg subcutaneously once a week for at least 3 months

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Peking Union Medical College Hospital

Information provided by (Responsible Party): Bing Han, Peking Union Medical College Ho...